|
|
Article: Schering-Plough and Sepracor In Licensing Agreement On CLARITIN(R) Metabolite
- Article from:
- PR Newswire
- Article date:
- December 8, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MADISON, N.J., and MARLBOROUGH, Mass., Dec. 8 /PRNewswire/ -- Schering- Plough Corporation (NYSE: SGP) and Sepracor Inc. (Nasdaq: SEPR) today announced a licensing agreement giving Schering-Plough exclusive worldwide rights to Sepracor's patents covering decarboethoxyloratadine (DCL), an active metabolite of loratadine that in pre-clinical studies has shown the potential for greater potency. Loratadine is the active agent in the five formulations of Schering-Plough's CLARITIN(R) nonsedating antihistamine.
Under terms of the agreement, Sepracor has exclusively licensed its DCL rights to Schering-Plough, which expects to develop and market the DCL product ...